RNA Interference and its Role in Cancer Therapy by Behzad Mansoori et al.
 
 
*Corresponding author: Behzad Baradaran, Tel:  +98 (411) 3364665, Email: baradaranb@tbzmed.ac.ir 
©2014  The  Authors.  This  is  an  Open  Access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  (CC  BY),  which  permits 
unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from 
the authors or the publishers. 
Adv Pharm Bull, 2014, 4(4), 313-321 
doi: 10.5681/apb.2014.046 
http://apb.tbzmed.ac.ir 
Advanced  
Pharmaceutical  
Bulletin
RNA Interference and its Role in Cancer Therapy 
Behzad Mansoori, Siamak Sandoghchian Shotorbani, Behzad Baradaran* 
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 
 
 
 
 
 
 
 
 
 
 
Introduction 
RNAi,  which  is  commonly  understood  as  RNA 
interference,  refers  to  a  member  of  non-coding  RNA 
(ncRNA). The term non-coding RNA (ncRNA) is used 
for RNA  that are  not  translated into  protein;  however, 
this  does  not  mean  that  non-coding  RNA  delivers  no 
performance.
1 New evidence suggests that a majority of 
the mammalian genome is transcribed into ncRNA and 
exclusively  2%  of  it  is  transcribed  into  mRNA  and 
translated  into  protein.
2-10  RNA  sequencing  studies 
showed  that  the  origin  of  ncRNAs  is  in  the  transcript 
antisense  protein-coding  genes,  bidirectional  promoter 
transcripts,  enhancer  and  repeated  sequences  areas 
transcription,  Intronic  transcripts.
11  Viruses  and  other 
double-stranded  RNA  microorganisms  insert  their 
genome  into  their  host  cells  or  artificially  synthesize 
double-stranded RNA.
12-14  Non-coding RNA  is  divided 
into two groups: 1- Small regulatory RNA and 2- Long 
non-coding RNA (Table 1). RNA interference (RNAi) is 
part  of  a  small  regulatory  RNA,  including  siRNA  and 
miRNA.
15 The discovery of RNA interference molecules 
indebted  to  Mr.  Fire's  and  Mello's  research  into  the 
C.elegans in 1998.
12 The advances in RNAi were made 
in following years leading eventually to the Physiology 
and Medicine Nobel Prize for Fire and Mello in 2006. 
Specific  gene  expression  silencing  by  RNAi  is  a 
mechanism of transcriptional regulation in the eukaryotic 
cell.  This  is  mediated  by  small  RNA  with  21-23 
nucleotides  length  called  siRNA  and  is  conserved  in 
terms  of  evolution  among  eukaryotes.  RNAi  seems  to 
protect  against  not  only  exogenous  genes  such  as 
microbial  organisms  genes  including  viral,  bacterial 
genes, but also endogenous genes such as transposons. 
The  other  roles  of  these  molecules  in  cells  involving 
gene expression regulation and cell growth control have 
been  demonstrated.
16-19  On  this  regard,  3  mechanisms 
have  been  identified  embodying:  1)  heterochromatin 
formation changes 2) Inhibition of translation of target 
mRNA 3) Degradation of the target mRNA. The second 
and third mechanisms are more divulged. Cancer is one 
of  the  main  targets  for  RNAi-based  therapy.  Several 
studies conducted invivo and invitro showed that RNAi- 
based  therapy  can  be  used  for  treating  single-gene 
disorders  and  those  with  overexpression  of  proteins.
20 
There are different types of small synthetic RNA used in 
cancer  therapy,  that  is,  siRNA,  shRNA  and  bishRNA. 
Such  cancer  therapy  outweighs  the  others  due  to  the 
silencing  mechanism,  specificity  and  lack  of  side 
effects.
21 
 
Mechanisms of gene silencing by siRNA 
SiRNA is produced in two stages, that is, starting and 
effecting  stages.  In  the  starting  stage,  a  long  double-
stranded  RNA  (500-200  bp)  is  cleaved  into  fragments 
with a length of 23-21 nucleotides by Dicer and siRNA 
is  produced.  SiRNA  is  an  functional  molecule.  The 
double-stranded  RNA  can  originate  from  the  viral 
genome, bacterial DNA or synthetic RNA produced by 
using bioinformatic data (Figure 1).
22,23 In the effecting 
stage, double-stranded siRNA are separated by helicase 
and  then  sense  strand  is  demarcated  by  endogenous 
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Abstract 
In todays’ environment, it is becoming increasingly difficult to ignore the role of cancer in 
social health. Although a huge budget is allocated on cancer research every year, cancer 
remains  the  second  global  cause  of  death.  And,  exclusively,  less  than  50%  of  patients 
afflicted with advanced cancer live one year subsequent to standard cancer treatments. RNA 
interference (RNAi) is a mechanism for gene silencing. Such mechanism possesses uncanny 
ability  in  targeting  cancer-related  genes.  A  majority  of  gene  products  involved  in 
tumorigenesis have recently been utilized as targets in RNAi based therapy. The evidence 
from these studies indicates that  RNAi application for targeting functional  carcinogenic 
molecules, tumor resistance to chemotherapy and radiotherapy is required in today’s cancer 
treatment. Knock downing of gene products by RNAi technology exerts antiproliferative 
and proapoptotic effects upon cell culture systems, animal models and in clinical trials in 
the most studies. The recognition of RNAi mechanism and the progress in this field leaded 
several new RNAi-based drugs to Clinical Trial phases. This has also developed genome 
based personalized cancer therapeutics. Hopefully, this type of treatment will work as one 
of the efficient one for cancer patients.  
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endonucleases  and  antisense  strand  is  directed  to  the 
RNA induced silencing complex (RISC). This complex 
is  then  directed  to  the  target  mRNA.  Argonate,  as  a 
member of RISC, by its ribonuclease activity from piwi 
region  degrades  the  target  mRNA.  Gene  expression 
terminates as long as target mRNA is broken by RISC. 
There are two pathways through which mRNA is broken. 
First,  they  might  be  broken  by  ribonuclease.  Second, 
they  can  be  connected  to  the  homologous  strand  and 
RNA polymerase forms double stranded RNA leading to 
the  continued  interference  pathway  (Figure  1).  By 
degradation of mRNA, expression of the target gene is 
suppressed, which is known as post-transcriptional gene 
silencing (PTGS).
22,23 After the discovery of the fact that 
siRNA targets gene expression unstably and transiently 
and finding the evidence that these molecules stimulate 
the innate immune response such as interferon, another 
post-transcriptional  silencing  technique  managed  by 
vector  called  shRNA  was  developed.  This  technique 
functions  through  frequently  gene  silencing  after 
transfection into genome by vectors.
24-26 
 
Table 1. Various classes of ncRNA in mammalian.
16-19,27-42 
Established ncRNA 
classes 
Common 
abbreviation  Size in nucleotides  Characteristics 
Long non-coding RNAs   lncRNAs  more than 200 nucleotides 
The widest class, action as sequence-specific tethers for protein 
complexes,  epigenetic  regulation  performance  and 
determination of the cell compartments and localization. 
Small interfering RNAs   siRNAs  21–22 nucleotides 
produced  by  Dicer  cleavage  of  200-500  nucleotides  length 
dsRNA duplexes, siRNAs form complexes with RISC involved in 
gene silencing, viral defense and transposon control. 
microRNAs   miRNAs  22 nucleotides 
produced  by  Dicer  and  drosha  cleavage  of  imperfect  RNA 
hairpins  encoded  in  long  primary  transcripts.  Associated  with 
RISC  and  primarily  involved  in  post-transcriptional  gene 
regulation. 
PIWI-interacting RNAs   piRNAs  26–30 nucleotides 
Dicer-independent small  RNAs,  restricted to  the  somatic  cells 
and germline bordering the germline, associated with PIWI and 
Argonaute  proteins  to  regulation  of  transposon  activity  and 
chromatin state. 
Promoter-associated 
RNAs 
PARs  - 
Inclusion of a set of long and short RNAs, promoter-associated 
RNAs  (PASRs)  and  transcription  initiation  RNAs  (tiRNAs)  that 
overlap  promoters  and  TSSs,  which  may  regulate  gene 
expression. 
Small nucleolar RNAs   snoRNAs  -  This guide rRNA methylation and pseudouridylation, and gene-
regulatory roles in some studies. 
Small nuclear RNAs  snRNAs 
approximately 150 
nucleotides 
Known as a U-RNA, the primary function of the processing of 
pre-mRNA  in  the  nucleus,  regulation  of  transcription  factors, 
RNA polymerase II and maintaining the telomeres. 
X-inactivation RNAs  xiRNAs  - 
Dicer-dependent small RNAs processed from Xist and Tsix the 
two  lncRNAs,  responsible  for  X-chromosome  inactivation  in 
placental mammals. 
Sno-derived RNAs   sdRNAs  - 
Small  RNAs,  being  Dicer-dependent  of  some  of  them,  and 
processed  from  small  nucleolar  RNAs  (snoRNAs),  action  as 
miRNA-like and translation regulation by some of them. 
microRNA-offset RNAs  moRNAs  20 nucleotides 
Small  RNAs,  derived  from  the  regions  related  to  miRNA  , 
unknown function. 
tRNA-derived RNAs  -  - 
Small RNAs processed by a conserved RNase (angiogenin) from 
tRNAs, induction of translational repression. 
MSY2-associated RNAs   MSY-RNAs  26-30 nucleotides 
associated with the germ cell-specific DNA/RNA binding protein 
MSY2. restricted to the germline, unknown function. 
Telomere small RNAs   tel-sRNAs  22 nucleotides 
Dicer-independent RNAs, derived from the G-rich sequence of 
telomeric repeats. a role in telomere maintenance. 
Centrosome-associated 
RNAs 
crasiRNAs  34-42 nucleotides 
Small RNAs, derived from centrosomes, a role in local chromatin 
modifications. 
 
Mechanisms of gene silencing by shRNA 
Unlike siRNA, shRNA is synthesized in the nucleus and 
then  is  transported  into  the  cytoplasm  for  final 
processing; thereafter, it binds to RISC and performs its 
activities.
43  ShRNA  activity  within  the  cell  is  shown 
schematically in Figure 2. Processing and maturation of 
shRNA  is  similar  to  those  of  miRNA.
44  ShRNA  is 
transcribed  by  RNA  polymerase  II  or  III  and  by  the 
means  of  RNA  polymerase  II  or  III  promoters  on  the 
expression  cassette.  Initial  transcription  of  RNA 
polymerase  II  promoter  is  produced  by  stem-loop-like 
structure  which  is  processed  by  complex  containing 
RNaseIII  family,  Drosha  and  double-stranded  RNA 
binding  protein  domain  (DGCR8).
45  ShRNA  hairpin 
complex  is  processed  by  the  abovementioned  enzyme 
and makes individual shRNAs by 2 over hang nucleotide 
at  the  3'  terminal.
46  This  stage  processes  a  molecule 
called pre-shRNA that is transported into cytoplasm by  
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exportin5/RanGTPase.
47,48 In the cytoplasm, pre-shRNA 
loaded  onto  RNaseIII  complexes  containing  Dicer, 
TRBP and PACT and the loop is cleaved and double-
stranded siRNA with two nucleotide over hang in the 3' 
is  produced.
48,49  The  complex  containing  Dicer  helps 
loading of  siRNA onto  the RISCs  Argo2  protein.  Pre-
shRNA is a component of RLC; therefore, pre-shRNA is 
potentially associated with the RLC. After loaded onto 
RLC, the passenger strand becomes separated. This also 
occurs in siRNA. Argonaute family constitutes the major 
portions  of  RISC  complex.
50,51  from  argonaute  family, 
only  Ago2  have  an  endonuclease  activity,  which  is 
necessary  for  cleavage  and  double  stranded  stem 
passenger release.
14,52,53 Other members of argonaute are 
Ago1,  Ago3,  Ago4,  which  do  not  have  endonuclease 
activity,  but  enters  RISC  and  act  independent  of  the 
cleavage. RISC complex have two functions, that is to 
say, function independent of the cleavage and function 
dependent  of  the  cleavage
52  (Figure  2).  Argonaute 
proteins  of  RISC  complex  not  only  are  involved  in 
loading  onto  siRNA  and  miRNA,  but  also  in 
transcriptional  and  post-transcriptional  silencing.  Ago 
protein  loading  onto  siRNA,  passenger  strand  and 
miRNA  are  targeted  on  mRNA  and  results  in  of 
endonuclease  activity  of  Ago2  and  cleavage  of  target 
mRNA
54,55 (Figure 2).Ago1, Ago3 and Ago4, which do 
not possess endonuclease activity; are located on 3' UTR 
of mRNA and inhibit translation by the processing target 
mRNA  in  P  bodies.
56,57  Details  the  suppression 
mechanisms of mRNA translation in the P bodies mRNA 
release from these bodies are still unknown. Adenylation 
of target mRNA causing mRNA instability occurs in P 
bodies.
  The  Coimmunoprecipitation  experiments  have 
shown that the RISC complex is strongly associated with 
polyribosomes and small ribosomal subunits.
58 Cleavage 
and conformation changes may be made in p bodies.
31,59 
 
Similarities and differences between the siRNA and 
shRNA 
The similarities between these two pathways exist in the 
function,  which  is  involvement  in  post-transcriptional 
silencing.  Both  siRNA  and  shRNA  use  common 
molecules  in  their  pathways  including  Dicer,  RISC 
complex and their aim is degradation of target mRNA. 
However,  there  are  significant  differences  shown  in 
Table 2.
21 
 
 
Figure 1. Long double-stranded RNA is cleaved into small interfering RNAs (siRNAs) by Dicer. This reaction needs ATP. SiRNA is then 
directed to RISC. The separation of the two strands needs ATP. Antisense strand is then directed to RISC 
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Figure 2. Schematic diagram of the shRNA gene silencing pathway. ShRNA is entered the cytoplasm by using expressing vector. Vector 
is transferred to the nucleus for transcription. Initial transcription is processed by Drosha-DGCR8 complex. Pre-shRNA is generated from 
pri-shRNA. Pre-shRNA is transported into cytoplasm by Ran exportin 5. Pre-shRNA is loaded onto Dicer, TRBP, PACT complex. Mature 
shRNA  is  generated  from  Pre-shRNA.  The mature shRNA  is  loaded  onto  Dicer,  TRBP, PACT complex.  The  complex  is  joined  to 
argounate protein in RISC, and provides RNA interference (41). 
 
 
Table 2. Differences between siRNA and shRNA
21 
scale  siRNA  shRNA 
Source  Synthetic  Nuclear expression 
Delivery 
Delivery to the cytoplasm using natural and 
synthetic polymers or lipids  
Delivery to the nuclear using viral or 
plasmid vectors 
Durability  Degradation of 99% of them in 46 hours   Expression up to 3 years 
Usage  Limited local or systemic injection  local or systemic injection 
Dose  High(nm)  Low(5 copies) 
Possibility of Specific Off-target effects  More than shRNA  Lower than siRNA 
Possibility of nonspecific Off-target effects 
High stimulation of immune system, 
inflammation, and cytotoxicity  
Low stimulation of immune system, 
inflammation, and cytotoxicity  
Application  Acute diseases  Chronic disease 
 
Bifunctional shRNA (bishRNA) 
BishRNA,  the  newly  designed  RNA  interference,  is 
being  increasingly  used  in  the  post-transcriptional 
silencing. BishRNA increases efficacy and durability of 
RNA interference and hastens gene expression silencing. 
Compared to shRNA,  bishRNA is able  to loaded  onto 
various RISC complexes. Such property leads to target 
mRNA degradation and inhibits translation of the mRNA 
individually.
21  BishRNA  shows  high  efficiency  and 
effectiveness  because  the  leading  (antisense)  strand  in 
bishRNA is loaded onto at least two RISC complexes, 
which increases the activity of gene silencing. Moreover, 
RISC  complex  loading  activates  both  cleavage 
dependent and independent pathways, and causes target 
mRNA  degradation  and  inhibits  target  mRNA 
translation
21 (Figure 3). 
 
The roles of RNA interference in cancer therapy 
Effectiveness of RNA interference in cancer therapy Has 
been  characterized  by  high  efficiency  and  potential, 
induction of silencing in the advanced stages of growth, 
transmission of silenced gene to the next generation, low 
cost compared to the other methods of gene therapy
60,61 
and high specificity compared to the other methods of  
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cancer  therapy  such  as  chemotherapy.  As  mentioned 
above, cancer is one of the main targets for RNAi-based 
therapy.  Oncogenes,  mutated  tumor  suppressor  genes 
and  several  other  genes  involved  in  tumor  progression 
are  good  targets  for  gene  silencing  by  RNAi-based 
therapy  due  to  the  precise  functional  mechanism,  high 
potential,  and  high  specificity  of  gene  silencing  by 
RNAi, and lack side effects compared to chemotherapies. 
The  major  advantage  of  RNAi  in  cancer  therapy  is 
targeting  multiple  genes  of  various  cellular  pathways 
involved in tumor progression.
62 Simultaneous inhibition 
of multiple genes is an effective approach to treat cancer 
as well as reduction of the possibility of multiple drugs’ 
resistance  caused  by  overdose  of  chemical  drugs. 
Another  advantage  of  this  type  of  treatment  is 
developing  suitable  personalized  drugs  for  a  specific 
patient.  Personalized  drugs  are  likely  to  be  more 
effective than others in controlling tumor growth.
62 Many 
studies have been done in the field of RNAi-based drugs 
leading  to  introduction  of  several  RNAi  based  drugs, 
which are now studied in the clinical trials. The studies 
conducted  on  animal  models  suggest  that  targeting 
essential  proteins  in  the  cell  cycle,  such  as  kinesin 
spindle protein (KSP) and polo-like kinase 1 (PLK1) by 
using  specific  siRNA  have  exhibited  potent  antitumor 
activity  observed  potent  antitumor  activity  in  both 
subcutaneous  and  hepatic  tumor  models.
58  KSP 
inhibition  causes  cell  cycle  termination  and  apoptosis 
induction
63  that  is  similar  to  PLK1  inhibition  inducing 
apoptosis.
62  Protein  kinase  N3  (PKN3)  has  been 
introduced as  a  valid  therapeutic target  in  cancer.  The 
inhibition  of  PKN3  reduces  lymph  node  metastases  in 
orthotopic  prostate  cancer  models.
64  Atu027  (siRNA-
lipoplex targeted against PKN3) has been administrated 
to  mice,  rats  and  non-human  primates.  And,  PKN3 
expression silencing resulted in significant tumor growth 
and  lymph  node  metastasis  inhibition.
63  Atu027  were 
used in animal models of metastatic lung cancer and the 
results  showed  the  inhibition  of  metastasis  after 
administration.
63  In  addition,  Atu027  was  evaluated  in 
the animal model of breast cancer metastasis to the lung 
and the results showed inhibition of lung metastasis.
65 A 
phase I clinical trial for treatment of solid cancers ended 
in  late  2012  and  the  next  phase  of  clinical  trials  has 
recently  been  started.  Table  3  provides  detailed 
information  about  the  current  status  of  RNAi-based 
drugs.
66-68 CALAA-01 is another RNAi-based drug that 
is being evaluated in phase I clinical trial. It is a specific 
siRNA against transferrin encapsulated by non-chemical 
nanoparticles  and  targets  the  M2  subunit  of 
ribonucleotide reductase (RRM2). The gene is involved 
in DNA replication. CALAA-01 binds to the transferrin 
receptor  and  siRNA  releases  RRM2-specific  after 
endocytosis,  leading  eventually  to  inhibition  of  RRM2 
expression and inhibition of proliferation of tumor cells 
expressing the transferrin receptor. In a phase I clinical 
trial of the drug, biopsies from patients with melanoma 
treated  with  the  drug  were  collected  and  the  results 
showed the nanoparticles inside biopsies and a reduction 
in RRM2 mRNA and RRM2 protein levels. At the end of 
phase I clinical trial, it was observed that administration 
of  siRNA  can  systemically  silence  carcinogenic  genes 
with  specific  targeting  of  tumor  cells.
69  ATN-RNA,  a 
160-bp double stranded RNA for targeting Tenasion-c, 
which  is  administered  locally,  is  currently  in  phase  I 
clinical  trial.
68  It  is  directly  administrated  into  the 
neoplastic tissues during glioma operation. It was found 
that the survival of patients promoted from 48.2 weeks to 
106.8 weeks after treatment. The authors also observed 
no neurological toxicity for this drug. FANG
TM vaccine, 
designed  by  bishRNA  technology,  can  be  used  for  ex 
vivo  silencing  of  Furin.  Furin  is  a  non-functional  and 
calcium-dependent  proprotein  and  is  essential  for 
proteolytic processing maturation of TGF-β isoform (β1, 
β2).  FANG
TM  vaccine  silences  Furin  and  boosts  GM-
CSF. The administration of FANG
TM vaccine into body 
causes  3  actions,  that  is,  extensive  presentation  of 
antigens,  Immune  stimulation  by  GM-CSF,  and 
inhibition of Immunosuppressive protein (TGF-β1, β2). 
The drug is still in clinical trial studies. In clinical trials, 
cancer  cells  are  collected  from  body  and  GM-
CSF/bishRNA  furin  is  transfected  into  expression 
plasmid by Electroporation method.
68 bishRNA-STMN1 
is a RNAi-based drug, whose phase I clinical trial has 
recently been started, and targets Stathmin1. Stathmin1 is 
a  149-amino  acid  protein  that  is  increased  in  tumor 
tissues  and  is  involved  in  tubulin-microtubule 
compartmentalization.  It  plays  a  role  in  M-phase 
entrance  and  exit,  and  cell  motility.  SiRNA  and 
ribozyme  can  target  stathmin1  and  it  was  shown  that 
inhibition  of  stathmin1  by  siRNA  and  ribozyme 
increases population of cells arrested in G2/M phase as 
well  as  inhibition  of  cell  cloning  and  apoptosis 
induction.
68 
 
Figure 3. Schematic diagram regarding the bifunctional shRNA. It 
is designed from two shRNA for an target mRNA, including : 1) 
one with perfect match and 2) one with mismatches at the central 
location (bases 9–12). The aim is to activate both RISC dependent 
cleavage and RISC independent cleavage pathways (41).   
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Table 3. Current Status of cancer siRNA based drug
66-68 
Company  Drug  Target  Vehicle  Disease  Phase 
Calando 
Pharmaceuticals 
CALAA-01  RRM2 
Cyclodextrin 
nanoparticle, TF, 
and PEG 
Solid tumors  I 
Silence 
Therapeutics AG 
Atu027  PKN3  siRNA-lipoplex 
Advanced solid 
cancer 
I 
Alnylam 
Pharmaceuticals 
ALN-VSP02  VEGF, KSP  SNALP  Solid tumors  I 
Silenseed Ltd.  siG12D LODER  KRAS  LODER polymer  PDAC  I 
Sataris Pharma 
and Enzon 
Pharmaceuticals 
EZN-2968  HIF-1, survivin  Nacked 
Advanced solid 
tumor or 
lymphoma 
I 
Tekmira  SNALP-PLK1  PLK1  SNALP  Solid tumors  I 
Duisburg 
University 
Bcr-Abl siRNA  Bcr-Abl  Anionic liposome  CML   
Gradalis Inc.  FANG vaccine 
Furin and 
GM-CSF 
Electroporation  Solid tumors  I 
Duke University  iPsiRNA 
LMP2, LMP7, 
MECL1 
Transfection 
Metastatic 
melanoma 
I 
Polish academy 
of sciences 
ATN-RNA  Tenascin-c  Nacked  Astrocytic tumor  I 
KSP, kinesin spindle protein; PKN3, protein kinase N3;  RRM2, M2 subunit of ribonucleotide reductase; VEGF, vascular  endothelial 
growth factor; HIF-1, hypoxia-induced factor; KRAS, V-ki-ras2 Kirsten rat sarcoma viral oncogene homolog; PLK1, polo-like kinase 1; 
IND, investigational new drug. Bcr-Abl, breakpoint cluster region- Abelson; GM-CSF, Granulocyte-macrophage colony-stimulating factor; 
LMP, latent membrane protein; MECL1, Multicatalytic Endopeptidase Complex-Like 1 
 
The future of cancer therapy by RNA interference 
Information  theory  is  a  new  strategic  and  helpful 
approach  to  cancer  treatment.
70  Clinical  responses  by 
siRNA-based drug were transient and often cause tumor 
recurrence or progression.
71 Heterogeneity of the tumor, 
multiple signaling pathways, cross talks and vertical and 
horizontal feedback loops challenge the gene targeting in 
most  solid  tumors.  Drug  resistance  caused  by  self-
treatment is also another problem.
72 In order to minimize 
drug  resistance,  at  least  three  different  treatments  are 
suggested.  With  this  strategy,  an  effective  therapy  by 
targeting triple factors reduces the risk of cancer.
68 Now 
researchers  are  developing  an  integrated  database  in  a 
participatory process for  the identification of  dominant 
signaling  pathways  and  involved  genes  based  on 
formulation of targeting three different factors. The next 
generation of RNAi-based therapies for cancer are based 
on  individual  treatments  (Figure  4).  The  approach  to 
cancer  will  be  RNAi  based  on  disruption  of  signaling 
pathways and developing of RNAi-based triple vaccine. 
This approach acts through damages to tumor growth by 
modifying the ratio of tumor/ T-cell activation, induction 
of apoptosis to increase antigen presenting, and reducing 
local  and  systemic  immunosuppression  associated  with 
immunotherapy. The effect of these drugs are not limited 
by  time  and  can  provide  long  time  memory  T-cell 
responses.
68 
 
 
Figure 4. Schematic diagram of the mechanism  implementing 
personalized  drugs  for  cancer.  The  process  is  started  by 
collecting a biopsy from the tumor, evaluating DNA, RNA and 
protein profiles. Tumor and normal tissue profiles are compared. 
By  Using  bioinformatic  data,  genetic  abnormalities,  impaired 
tumor-specific  pathways  are  identified.  Two-pronged  approach 
(target  therapy  and  vaccine)  administered  to  each  patient  for 
having effective treatment (74). 
 
Conclusion 
Efficacy and clinical safety of several main components 
of  RNAi  technologies  such  as  siRNA,  shRNA  and 
bishRNA have been demonstrated. In addition, specify to 
target  and  anticancer  activity  regarding  RNAi 
technologies  have  been  proven  in  animal  models.  To 
date,  systemic  delivery  to  tumor  targets  other  than  the 
liver has resulted in many problems; thus, researchers are  
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now examining safe and effective delivery approaches of 
these  molecules  to  their  target  tissues.  The  results  of 
phase  I  clinical  trial  of  several  RNAi-based  drugs  are 
available and shows the safety of treatment. All in all, It 
is postulated that RNAi-based therapy will be used as a 
new method of cancer therapy in the near future. 
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